Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

After intravenous administration, Irinotecan is metabolised to SN‑38, which binds to the DNA‑topoisomerase I complex. This prevents the re‑ligation of single‑strand DNA breaks during replication, causing accumulation of DNA damage and ultimately leading to cancer cell death.

The dose of Irinotecan Kabi is determined by the prescribing oncologist based on the patient’s body surface area, liver function, and treatment protocol. Typical regimens involve an intravenous infusion given every two weeks, but exact dosing must be individualized by a qualified healthcare professional.

Safety data for Irinotecan during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential therapeutic benefit justifies any potential risk to the fetus or infant, and breastfeeding is generally not recommended.

To request Irinotecan Kabi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain logistics if needed), and import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as oxaliplatin (a platinum compound) or fluoropyrimidines (e.g., 5‑FU). While all are used in colorectal cancer, Irinotecan’s mechanism targets DNA replication enzymes, offering an alternative resistance profile and often being combined with other agents for synergistic effect.

Irinotecan Kabi should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept under controlled temperature conditions during transport.

The drug is supplied as a sterile lyophilized powder that is reconstituted with a suitable diluent. It is then administered by a qualified healthcare professional as an intravenous infusion over a prescribed period, usually lasting 30 to 90 minutes depending on the treatment protocol.

The most critical adverse events include severe neutropenia or febrile neutropenia, which can lead to life‑threatening infections, and severe diarrhea or colitis that may cause dehydration and electrolyte imbalance. Prompt medical attention is required if fever, persistent diarrhea, or signs of infection develop.

Patients with known hypersensitivity to Irinotecan or any of its excipients should avoid the drug. Individuals with severe hepatic impairment, confirmed UGT1A1 deficiency (e.g., *28/*28 genotype) that predisposes to high SN‑38 exposure, or those currently receiving other myelosuppressive therapies should be evaluated carefully before use.